Ustekinumab for pyoderma gangrenosum

Archives of Dermatology

Volumn 148, Issue 5, 2012, Pages 655-

  Kluger, Nicolas ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INTERLEUKIN 23; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYODERMA GANGRENOSUM; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INTERLEUKIN-23; MOLECULAR TARGETED THERAPY; PYODERMA GANGRENOSUM;

EID: 84861357326     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.3249     Document Type: Note

References (5)

1. Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203-1205.
2. Wollina U, Haroske G. Pyoderma gangraenosum. Curr Opin Rheumatol. 2011;23(1):50-56.
3. Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology. 2007;215(3):245-251. (Pubitemid 47378994)
4. Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol. 2007;46(10):1095-1099. (Pubitemid 47506384)
5. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53(2):273-283. (Pubitemid 40979585)